Solid Biosciences Inc. cash flow to debt ratio of -738.57% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Solid Biosciences Inc.'s free cash flow has decreased 56.40% from $-100.67M last year to $-157.44M, signaling decreasing performance

Solid Biosciences Inc.'s debt to equity ratio is 0.05, which means that the company's assets are healthy financed, signaling financial stability.

Solid Biosciences Inc.'s debt has decreased relative to shareholder equity from 0.18 last year to 0.05 today, signaling strengthened financials

Solid Biosciences Inc. has a net cash position, so leverage is healthy.

Solid Biosciences Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Solid Biosciences Inc. has insufficient data to evaluate this check.

Solid Biosciences Inc.'s short-term assets of $205.46M exceed its short-term liabilities of $33.47M

Solid Biosciences Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Solid Biosciences Inc.'s return on equity of -72.28%, is lower than 15.00%, indicating bad performance

Solid Biosciences Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Solid Biosciences Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Solid Biosciences Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Solid Biosciences Inc. has negative free cash flow, indicating cash burn

Solid Biosciences Inc.'s yearly earnings has decreased 39.80% since last year from $-124.70M to $-174.32M, signaling decreasing performance

Solid Biosciences Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -53.81% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Solid Biosciences Inc.'s 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years

Solid Biosciences Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Solid Biosciences Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Solid Biosciences Inc. has insufficient data to evaluate this check.

Solid Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Solid Biosciences Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Solid Biosciences Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Solid Biosciences Inc. has insufficient data to evaluate this check.

Solid Biosciences Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Solid Biosciences Inc. has a price-to-book ratio of 3.29x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Solid Biosciences Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue